A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase 2, open-label, dose optimization/expansion study to assess the preliminary efficacy and safety of SAR445877 as a monotherapy for Chinese participants aged at least 18 years with advanced Gastric Cancer(GC)/Gastroesophageal Junction cancer (GEJ). Participants with advanced GC/GEJ who relapsed to at least 1 prior regimen which may or may not include an anti-PD1/PD-L1-based treatment depending on local standard of care, regardless combined positivity score (CPS) will be randomized in this study. In this study, SAR445877 will be assessed as a monotherapy in approximately 30 participants with advanced unresectable or metastatic GC or Siewert Type 2 and 3 GEJ, and for whom receiving the standard of care (SOC) is not in his or her best interest, or where no SOC is established. Human epidermal growth factor receptor 2 (HER2) positive cases will not be eligible unless they have progressed on a HER2 targeted therapy. Those participants should have received at least 1 prior line of anti-cancer treatment which may or may not include an anti-PD1/PD-L1-based treatment depending on local standard of care. Metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cases are not eligible.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony histologicznie lub cytologicznie zaawansowany lub przerzutowy rak żołądka
- •Poprzednio nieudane leczenie - co najmniej jedna linia poprzedniej terapii przeciwnowotworowej
- •Mierzalne ognisko nowotworu widoczne w badaniach obrazowych
- •Status zdrowotny pozwalający na uczestnictwo w badaniu
✗ Disqualifies
- •Zły ogólny stan zdrowia uniemożliwiający uczestnictwo w badaniu
- •Spodziewana długość życia poniżej 3 miesięcy
- •Inne nowotwory wymagające aktywnego leczenia w ciągu ostatnich 2 lat
- •Przerzuty do mózgu lub opon mózgowych
- •Historia ciężkich reakcji immunologicznych na poprzednie immunoterapie
- •Przewlekłe stosowanie wysokich dawek kortykosteroidów
- •Poważne problemy kardiologiczne lub naczyniowe
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Investigational Site Number : 1560001
Shanghai, China
Trial contact
Trial Transparency email recommended (Toll free for US & Canada)
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.